Case Report
The American Journal of Gastroenterology (2007) 102, 449–451; doi:10.1111/j.1572-0241.2006.00937.x
Suppressive Anti-HCV Therapy for Prevention of Donor to Recipient Transmission in Stem Cell Transplantation
Sri Naveen Surapaneni MD, MPH, Parameswaran Hari MD, Josh Knox PA-C, Jack Daniel RN and Kia Saeian MD, MSc
Divisions of Hematology & Oncology, Gastroenterology & Hepatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Correspondence: Kia Saeian, MD, MSc, FACG, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, 9200 W Wisconsin Ave., Milwaukee, WI 53226.
Received 8 July 2006; Accepted 23 August 2006.
Abstract
A 48-yr-old man with acute myeloid leukemia (AML) required urgent allogeneic hematopoietic stem cell transplantation because of failed attempts to induce remission via chemotherapy. He had an HLA identical donor sister who was hepatitis C virus (HCV) RNA positive. In order to prevent HCV transmission to her brother, the donor was treated with weekly injections of pegylated interferon alfa-2b (150 
g subcutaneously every week) and daily ribavirin (1 g/day) for 5 wk at which time her qualitative polymerase chain reaction (PCR) was negative. Her stem cells were successfully grafted into the recipient. The recipient remained HCV PCR negative after transplant until death from relapsed AML.
